Lv1
95 积分 2021-11-14 加入
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
5天前
已完结
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
3个月前
已完结
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial
3个月前
已完结
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
3个月前
已完结
The evolving landscape of metastatic HER2-positive, hormone receptor-positive breast cancer
7个月前
已完结
Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models
1年前
已完结
Pathological complete response and long term clinical benefit in breast cancer
2年前
已完结
Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes
2年前
已完结
Do We Need Support in Prepectoral Breast Reconstruction? Comparing Outcomes with and without ADM
2年前
已关闭
Meta-analysis of prepectoral implant-based breast reconstruction: guide to patient selection and current outcomes
3年前
已完结
皖公网安备34019202002308
